These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 20546528

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64. [Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].
    Liu F, Ding Y, Yin W.
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Dec; 15(12):1109-12. PubMed ID: 24342209
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
    Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
    J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
    [Abstract] [Full Text] [Related]

  • 68. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with kawasaki disease.
    Seki M, Kobayashi T, Kobayashi T, Morikawa A, Otani T, Takeuchi K, Ayusawa M, Tsuchiya K, Yasuda K, Suzuki T, Shimoyama S, Ikeda K, Ishii Y, Arakawa H.
    Pediatr Infect Dis J; 2011 Feb 06; 30(2):145-7. PubMed ID: 20802375
    [Abstract] [Full Text] [Related]

  • 69. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
    Cardiovasc Ther; 2021 Feb 06; 2021():6660407. PubMed ID: 34239607
    [Abstract] [Full Text] [Related]

  • 70. [Clinical features of recurrent Kawasaki disease in 20 children].
    Zou LX, Gong FQ.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Oct 06; 10(5):617-9. PubMed ID: 18947484
    [Abstract] [Full Text] [Related]

  • 71. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease.
    Ichiyama T, Ueno Y, Hasegawa M, Ishikawa Y, Matsubara T, Furukawa S.
    Rheumatology (Oxford); 2005 Mar 06; 44(3):314-7. PubMed ID: 15572393
    [Abstract] [Full Text] [Related]

  • 72. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
    Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A.
    J Pediatr; 2006 Sep 06; 149(3):336-341. PubMed ID: 16939743
    [Abstract] [Full Text] [Related]

  • 73. Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
    Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Honda T, Onouchi Y, Terai M, Hata A.
    Cytokine; 2012 Dec 06; 60(3):681-5. PubMed ID: 22944461
    [Abstract] [Full Text] [Related]

  • 74. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease.
    Minami T, Suzuki H, Takeuchi T, Uemura S, Sugatani J, Yoshikawa N.
    J Pediatr; 2005 Jul 06; 147(1):78-83. PubMed ID: 16027700
    [Abstract] [Full Text] [Related]

  • 75. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience.
    Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R.
    J Paediatr Child Health; 2004 Jul 06; 40(9-10):524-9. PubMed ID: 15367145
    [Abstract] [Full Text] [Related]

  • 76. High neutrophil : lymphocyte ratio is associated with refractory Kawasaki disease.
    Cho HJ, Bak SY, Kim SY, Yoo R, Baek HS, Yang S, Hwang IT, Ban JE.
    Pediatr Int; 2017 Jun 06; 59(6):669-674. PubMed ID: 28097746
    [Abstract] [Full Text] [Related]

  • 77. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
    J Microbiol Immunol Infect; 2007 Oct 06; 40(5):395-400. PubMed ID: 17932598
    [Abstract] [Full Text] [Related]

  • 78. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
    Wei M, Huang M, Chen S, Huang G, Huang M, Qiu D, Guo Z, Jiang J, Zhou X, Yu Q, Guo Y, Fu L, Gao W, Li F.
    Pediatr Cardiol; 2015 Aug 06; 36(6):1166-72. PubMed ID: 25812827
    [Abstract] [Full Text] [Related]

  • 79. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y, Mori M, Hara T, Inaba A, Oba MS, Yokota S.
    Ther Apher Dial; 2015 Apr 06; 19(2):171-7. PubMed ID: 25257673
    [Abstract] [Full Text] [Related]

  • 80. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
    Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
    Paediatr Int Child Health; 2018 Aug 06; 38(3):209-212. PubMed ID: 29768976
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.